June 10, 2025, Innovative Medical Technology CompanyAtraverse Medical Inc. AnnouncementCompleted a follow-up financing of $29.4 million (approximately 210 million RMB).This round of financing brings together angel investors, family offices, renowned venture capital firm Mohan Growth Partners, and several medical technology entrepreneurs, bringing the company's total funding to over 40 million US dollars since its inception.

The company stated that the proceeds from the financing will be used to expand the manufacturing capacity of the Hotwire left-heart guiding system, advance the regulatory approval of the accompanying radiofrequency generator, build a commercialization team, and accelerate the development of the next-generation product. With the completion of this round of financing, the company has also transitioned from an early clinical stage company to the initial commercialization phase.

# Financing Structure and Development Plan

Atraverse Medical, Inc. has completed a $29.4 million financing round jointly participated by multiple parties, including Mohan Growth Partners, and also attracted entrepreneurs like Jean-Luc Pageard, who have been deeply involved in the commercialization of cardiac rhythm devices. The funds from this round will support several core areas:

• Manufacturing Capacity Expansion: Establish an initial production system for the Hotwire system to meet the usage requirements of a limited market release;

• Development of Supporting Equipment: The proprietary RF generator is nearing the completion of development, and the company expects to submit it for FDA approval in the second quarter of 2025, with the goal of further enhancing the autonomy of Hotwire operational control.

• Team Building: By the end of 2024, the company has expanded to 15 employees, and plans to continue recruiting sales and clinical application specialists in 2025.

• Global Market Research: Although the current main market is in the U.S., the company is also evaluating the possibilities of regulatory pathways in Europe and the Asia-Pacific region.

Atraverse stated that once the配套射频发生器is approved, the company will quickly advance the full market launch of Hotwire and explore its application potential in mitral valve and occlusion-related surgeries.

# Market Demand: The Complexity of Left Heart Guidance Procedures Needs Simplification

Left heart access is a key step in multiple types of interventional procedures such as atrial fibrillation ablation, left atrial appendage closure, and mitral valve repair. It typically requires puncture through the femoral vein and entry into the left atrium via the interatrial septum to complete catheter positioning. However, this process traditionally relies onMulti-step guidewire exchange and independent puncture instruments,Multiple operation steps, strong dependence on the operator, increased risk of air embolism, positioning deviation, and intraoperative complications.

According to Life Science Intelligence data, in 2023, there were approximately 800,000 valve replacement procedures, 500,000 congenital heart defect repairs, and 1.3 million ablation surgeries performed globally, with about 80% of the procedures involving left-heart access processes.It is estimated that globally, there is a need to perform1.5–2 million transseptal puncture procedures.

Doctors and manufacturers are seeking a "modular" and "guidewire-integrated" solution to improve efficiency, reduce radiation and complications, and ensure compatibility with various sheaths and procedural workflows.

# Hotwire System: Integrated Design Revolutionizes Left Heart Access Procedures

The Hotwire system developed by Atraverse is aRadiofrequency Guidewire Left Heart Guidance DeviceThe core design integrates the puncture function within the guidewire, serving a dual role: as an RF tool for atrial septal puncture and as a structural rail for subsequent catheter operations, enabling "zero exchange" transseptal guidance.

The system has the following key features:

• Zero-Switch Workflow: After completing the puncture, there is no need to replace the guidewire; directly guide the subsequent instruments, significantly simplifying the operational steps;

• Universal Sheath Compatibility: Compatible with a variety of commercially available guiding sheaths, enhancing the operator's choice flexibility and facilitating rapid integration into existing procedural workflows;

• Enhanced Imaging and Stiffness Optimization: The brightness increases by approximately 25% under echocardiography; the rail stiffness is twice that of traditional guidewires, which facilitates the smooth delivery of highly rigid instruments;

• Intraoperative Safety: The structural design can reduce the risk of air embolism and improve the precision of left atrial access by optimizing puncture positioning.

The product was co-designed by Steven Mickelsen, Ph.D., founder of Farapulse, and Eric Sauter, co-founder of Atraverse Medical, Inc., with the intention of reconstructing the left atrial guiding pathway from both structural and procedural perspectives.

# Clinical Data and Real-World Validation

Hotwire received FDA 510(k) clearance in May 2024.The first approved zero-exchange radiofrequency transseptal guiding system.As of April 2025, the system has been successfully used in over 250 surgeries across multiple medical institutions in the United States, covering 10 types of commonly used guiding sheaths, and has received extensive feedback from operators.

During the 2025 Heart Rhythm Society (HRS) Annual Meeting in April, Dr. Devi Nair, Director of Cardiac Electrophysiology at St. Bernards Medical Center, presented the results of the Hotwire first-in-human multicenter trial:

• Guidance Success Rate 100%：Left-heart guidance was successfully completed in all surgeries;

• Zero Serious Device-Related Incidents：No significant complications were observed;

• Positive feedback from the operator：The doctor reporting system is intuitive and easy to learn, operates smoothly, and can be quickly integrated into existing workflows.

Previously, at the AF Symposium international atrial fibrillation conference in January 2025, the Hotwire system was showcased through two late-stage research posters, focusing on impedance-terminated energy modulation and human application experience, further validating its performance advantages in energy consumption optimization and efficiency improvement.

Vivek Y. Reddy, MD, Director of the Cardiac Arrhythmia Service at Mount Sinai Hospital in New York, noted in public comments that Hotwire strikes a balance between "structural innovation" and "operational intuitiveness," and is expected to become the standard guiding approach in future electrophysiology and structural heart procedures.

# AboutAtraverse Medical

Atraverse Medical, Inc. was founded in 2022 and is headquartered in San Diego, California. It was co-founded by Dr. Steven Mickelsen, John Slump (current CEO), and Eric Sauter (Chief Operating Officer). The trio previously led the creation of Farapulse and successfully sold it to Boston Scientific, accumulating extensive experience in innovation and commercialization pathways in electrophysiology procedures.

Atraverse's mission is to reshape the left-heart guiding pathway through system-level process redesign, using the Hotwire system as an entry point, to build a new-generation transseptal platform featuring "interface universality + structural optimization + pathway integration."

As of now, the company has completed three rounds of financing and received FDA approval, and is currently in the transition phase from clinical transformation to scaled promotion. Whether it will further expand its product line and build an integrated platform in the future still depends on regulatory progress and market feedback.